AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. HALO
  4. [SCHEDULE 13G/A] Halozyme Therapeutics, Inc. SEC Filing

[SCHEDULE 13G/A] Halozyme Therapeutics, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A
Rhea-AI Filing Summary
Analyzing...
Positive
  • None.
Negative
  • None.

Filing content is currently unavailable.

Source:

Stock HALO logo
Halozyme Thrp

NASDAQ:HALO

HALO Rankings

#1431 Ranked by Market Cap
N/A Ranked by Dividends

HALO Latest News

Jul 23, 2025
European Commission Approved DARZALEX Faspro庐 for Adult Patients with Smouldering Multiple Myeloma
Jul 22, 2025
Halozyme to Report Second Quarter 2025 Financial and Operating Results
Jun 30, 2025
Halozyme Therapeutics Added to Russell 1000庐 Index
Jun 20, 2025
Halozyme Announces argenx Received European Commission Approval for VYVGART庐 Subcutaneous Injection with ENHANZE庐 for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
May 28, 2025
Halozyme to Participate at Upcoming Investor Conferences

HALO Latest SEC Filings

Jul 10, 2025
[Form 4] Halozyme Therapeutics, Inc. Insider Trading Activity
Jun 24, 2025
[Form 4] Halozyme Therapeutics, Inc. Insider Trading Activity
Jun 20, 2025
[144] Halozyme Therapeutics, Inc. SEC Filing

HALO Stock Data

7.09B
121.85M
1.16%
102.39%
7.92%
Biotechnology
Biological Products, (no Disgnostic Substances)
United States
SAN DIEGO